Loading clinical trials...
Loading clinical trials...
A Phase I, Randomized, Investigator/Participant-blind, Parallel-group, Placebo-controlled, Single and Multiple Ascending Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7806881 in Healthy Participants
Conditions
Interventions
RO7806881
Placebo
Locations
1
New Zealand
New Zealand Clinical Research - Christchurch
Christchurch, New Zealand
Start Date
December 22, 2025
Primary Completion Date
March 1, 2027
Completion Date
March 1, 2027
Last Updated
April 15, 2026
NCT00104325
NCT07118891
NCT01399385
NCT07295717
NCT03807401
NCT05196061
Reference Study ID Number: BP46089 https://forpatients.roche.com/
CONTACT
888-662-6728global-roche-genentech-trials@gene.comLead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions